DMK Pharmaceuticals Corporation Common Stock
DMK was delisted on the 6th of February, 2024.
53 hedge funds and large institutions have $12.8M invested in DMK Pharmaceuticals Corporation Common Stock in 2021 Q1 according to their latest regulatory filings, with 17 funds opening new positions, 12 increasing their positions, 6 reducing their positions, and 5 closing their positions.
240% more first-time investments, than exits
New positions opened: 17 | Existing positions closed: 5
235% more capital invested
Capital invested by funds: $3.81M → $12.8M (+$8.97M)
100% more repeat investments, than reductions
Existing positions increased: 12 | Existing positions reduced: 6
29% more funds holding
Funds holding: 41 → 53 (+12)
16% less call options, than puts
Call options by funds: $996K | Put options by funds: $1.19M
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Vanguard Group
Malvern,
Pennsylvania
|
+$4.08M |
| 2 |
Renaissance Technologies
New York
|
+$915K |
| 3 |
BlackRock
New York
|
+$617K |
| 4 |
Geode Capital Management
Boston,
Massachusetts
|
+$577K |
| 5 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
+$549K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
GCP
GSA Capital Partners
London,
United Kingdom
|
-$250K |
| 2 |
Qube Research & Technologies (QRT)
London,
United Kingdom
|
-$154K |
| 3 |
UBS Group
Zurich,
Switzerland
|
-$20.9K |
| 4 |
BRWA
B. Riley Wealth Advisors
Boca Raton,
Florida
|
-$14.5K |
| 5 |
Osaic Holdings
Scottsdale,
Arizona
|
-$9.97K |
DMK Hedge Fund Activity: Q1 2021 in Review
53 of the 5,695 institutional investors tracked by Wall St. Rank reported a position in DMK Pharmaceuticals Corporation Common Stock (DMK) for Q1 2021, worth a combined $12.8M — up 235% from $3.81M a quarter earlier.
Buyers outnumbered sellers: 17 funds opened new DMK positions and 5 closed out — a net gain of 12 holders — while 12 added to existing stakes and 6 trimmed.
The largest buyer was Vanguard Group, adding an estimated $4.08M. The largest seller was GSA Capital Partners, exiting entirely with an estimated $250K sold.
- 53 institutional investors held DMK Pharmaceuticals Corporation Common Stock (DMK) as of Q1 2021, up from 41 in Q4 2020.
- Funds reported $12.8M of DMK Pharmaceuticals Corporation Common Stock stock for Q1 2021, up 235% quarter-over-quarter.
- 17 funds opened new DMK Pharmaceuticals Corporation Common Stock positions in Q1 2021 and 5 closed out, a net change of +12 holders.
- The largest DMK Pharmaceuticals Corporation Common Stock buyer in Q1 2021 was Vanguard Group, an estimated $4.08M added.
- The largest DMK Pharmaceuticals Corporation Common Stock seller in Q1 2021 was GSA Capital Partners, an estimated $250K sold.
Based on aggregated 13F filings for Q1 2021.